APOB Antikörper

Produktnummer ABIN965573

Für dieses Produkt ist 1 Publikation verfügbar. Der Maus-Monoklonal Anti-APOB-Antikörper wurde für WB, ELISA, FACS und IF validiert. Er ist geeignet zum Nachweis von APOB in Proben aus Human. }

Kurzübersicht für APOB Antikörper (ABIN965573)

Target: APOB (Apolipoprotein B (APOB))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser APOB Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunofluorescence (IF)

Klon: 6G6

Produktdetails anti-APOB Antikörper

Aufreinigung: Ascitic fluid

Immunogen: Purified recombinant fragment of human ApoB expressed in E. Coli.

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Western Bloting: 1/500 - 1/2000.
Immunofluorescence: 1/200 - 1/1000.
Flow cytometry: 1/200 - 1/400.
ELISA: Propose dilution 1/10000.
Not yet tested in other applications.
Determining optimal working dilutions by titration test.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Referenzen für anti-APOB Antikörper (ABIN965573)

Peterson, Mack, Hall, Alsup, Alexander, Sully, Sawires, Cheung, Otto, Gresham: "Apolipoprotein B Is an innate barrier against invasive Staphylococcus aureus infection." in: Cell host & microbe, Vol. 4, Issue 6, pp. 555-66, (2008) (PubMed).

Details zu APOB

Target: APOB (Apolipoprotein B (APOB))

Andere Bezeichnung: ApoB

Hintergrund: This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels.
Synonyms: FLDB, LDLCQ4

Molekulargewicht: 516kDa

Gen-ID: 338

Pathways: Lipid Metabolism